Experimental drug trial aims to tame debilitating leprosy Flare-Ups
NCT ID NCT07172659
Summary
This study is testing an unapproved drug called dovramilast to see if it can better control painful skin flare-ups caused by leprosy type 2 reaction. It will compare two doses of the new drug against current standard treatments over 12 weeks in 45 adults. The main goal is to see if the new drug can safely reduce skin lesions by at least 75% without needing rescue medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHEMA NODOSUM LEPROSUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli
Abomey-Calavi, Benin
-
Chr de Divo
Divo, Côte d’Ivoire
-
Harborview Medical Center, University of Washington
Seattle, Washington, 98104, United States
-
Philippine General Hospital, University of the Philippines, Manila
Manila, Philippines
-
Universitas Gadjah Mada
Yogyakarta, Indonesia
-
University of Southern California
Los Angeles, California, 90007, United States
Conditions
Explore the condition pages connected to this study.